Selective inhibitors for cyclin-dependent kinases

Details Selective inhibitors for cyclin-dependent kinases Selective inhibitors for cyclin-dependent kinases

2009-12-04

2011-11-29

Fetterolf, Brandon (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S281000, C435S194000

Reexamination Certificate

active

08067424

ABSTRACT:
This invention provides a class of compounds which are useful for specifically inhibiting cyclin-dependent kinases. This class of compounds finds use in treating diseases resulting from inappropriate activity of cyclin-dependent kinases, including cancer, viral infections (e.g., HIV) neurodegenerative disorders (e.g. Alzheimer's disease), and cardiovascular disorders (e.g. atherosclerosis). Moreover, certain members of this class are particularly useful for inhibiting cyclin-dependent kinase 7 and are especially useful for the treatment of breast cancer.

REFERENCES:
patent: 2004/0209878 (2004-10-01), Guzi et al.
patent: WO 2005/077954 (2005-08-01), None
Bour, G., “Cyclin H binding to the RARalpha activation function (AF)-2 domain directs phosphorylation of the AF-1 domain by cyclin-dependent kinase 7,”Proc. Natl. Acad. Sci., U.S.A., 102(46): 16608-16613 (2005).
Chen, D., et al., “Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7,”Mol. Cell., 6(1): 127-137 (2000).
Devault, A., et al., “MAT1 (menage á trois) a new RING finger protein subunit stabilizing cyclin H-cdk7 complexes in starfish and Xenopus CAK,”EMBO J., 14(20): 5027-36 (1995).
Fischer, P.M., “The use of CDK inhibitors in oncology: a pharmaceutical perspective,”Cell Cycle, 3(6): 742-6 (2004).
Fisher, R.P., et al., “Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase,”Cell, 83(1): 47-57 (1995).
Fisher, R.P., “Secrets of a double agent: CDK7 in cell-cycle control and transcription,”J. Cell Sci., 118(22): 5171-5180 (2005).
Iben, S., et al., “TFIIH plays an essential role in RNA polymerase I transcription,” Cell, 109(3): 297-306 (2002).
Lolli, G., and Johnson, L.N., “CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?”Cell Cycle, 4(4): 572-577 (2005).
Losiewicz, M.D., et al., “Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275,”Biochem. Biophys. Res. Commmun., 201(2): 589-595 (1994).
Knockaert, M., et al., “Pharmacological inhibitors of cyclin-dependent kinases,”Trends Pharmacol. Sci., 23(9): 417-425 (2002).
Wang, S., et al., “Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer,”Tetrahedron: Asymmetry, 12(20): 2891-2894 (2001).
Williamson, D.S., et al., “Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2,”Bioorg. Med. Chem. Lett., 15(4): 863-867 (2005).

Affiliated with

Also associated with

Rating

Selective inhibitors for cyclin-dependent kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Selective inhibitors for cyclin-dependent kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective inhibitors for cyclin-dependent kinases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4289122